Cetirizine injection for treating acute urticaria

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy and safety of cetirizine hydrochloride injection in patients with acute urticaria. Participants are randomly assigned to receive either cetirizine or diphenhydramine hydrochloride to compare their effects on symptoms. The study focuses on individuals aged 18 to 65 who have been diagnosed with acute urticaria and experience significant itching and wheals. The trial aims to determine if cetirizine provides better relief than the standard treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age range: 18 - 65 years old (inclusive of the threshold value), gender not limited;
2. Diagnosed with acute urticaria (the definition of acute urticaria: spontaneous wheals and/or angioedema attacks ≤ 6 weeks);
3. At screening，the severity score of pruritus of the patient was ≥ 1 point ;
4. At screening，the degree score of wheals/erythema of the patient assessed by the investigator was ≥ 1 point ;
5. Be willing and able to give informed consent.

Exclusion Criteria:

1. Patients in whom an antihistamine are contraindicated (such as those with angle-closure glaucoma, symptomatic benign prostatic hyperplasia, etc.);
2. Patients who used H1 antagonists (such as diphenhydramine, cetirizine, loratadine, fexofenadine, levocetirizine, desloratadine, etc.) within 2 hours before randomization;
3. Patients who used H2 antagonists (such as cimetidine, ranitidine, famotidine, roxatidine, etc.) within 2 hours before randomization;
4. Patients who used doxepin within 2 hours before randomization;
5. Patients who received steroid hormone treatment for acute allergic reactions within 4 hours before randomization;
6. Patients who used epinephrine within 20 minutes before randomization;
7. Patients who are known to be allergic to hydroxyzine, cetirizine, levocetirizine, diphenhydramine;
8. Pregnant or lactating women; or those who have a pregnancy plan or plan to donate sperm/eggs from the screening day to the end of medication within 1 month; or those who are unwilling to take one or more contraceptive measures from the screening day to the end of medication within 1 month;
9. Patients with urticarial drug eruption;
10. Patients with acute urticaria who have concurrent symptoms such as laryngeal edema, allergic asthma, anaphylactic shock during screening;
11. Patients with urticarial vasculitis, hereditary angioedema, antihistamine-resistant urticaria or skin diseases that interfere with the evaluation of treatment efficacy during screening;
12. Patients with a history of immunodeficiency;
13. Patients with other major medical conditions (such as blood diseases, cardiovascular and cerebrovascular diseases, liver diseases, kidney diseases, etc.) or mental disorders and judged by the investigator to be unsuitable to participate in this study;
14. Patients who are concurrently using P-glycoprotein inhibitors (such as cyclosporine, itraconazole, dronedarone, amiodarone, quinidine, verapamil, etc.) during screening;
15. Patients who participated in other clinical trials within 3 months before screening (excluding those who only participated in the screening of the clinical trial but did not use the trial drugs or devices);
16. Patients with acute urticaria accompanied by fever during screening;
17. Patients engaged in dangerous jobs such as driving, high-altitude work, mechanical operation, etc., and cannot stop within 48 hours after medication;
18. Other various situations.

Where it's running

• Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
  Beijing, Beijing Municipality, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Higher-dose cetirizine for acute hives in adults

  This study tests whether taking 40 mg of cetirizine per day is better at relieving acute urticaria symptoms in adults than the standard 10 mg daily dose.

  Recruiting University of Phayao · Phayao, Mueang · NCT07236372

• Targeting B cells and plasma cells in lupus with a dual-action antibody

  A new injectable therapy (F182112) will be tested in adults with systemic lupus erythematosus to see if it can help by hitting both CD3 on immune cells and BCMA on B cells and plasma cells.

  Recruiting Phase 1 Shandong New Time Pharmaceutical Co., LTD · Shanghai · NCT07829614

• F520 with paclitaxel and carboplatin as first-line therapy for cancer of unknown primary

  This trial tests whether adding F520 to standard chemotherapy can improve responses in adults with cancer of unknown primary who have not yet received systemic therapy.

  Recruiting Phase 2/3 Shandong New Time Pharmaceutical Co., LTD · Shanghai, Shanghai Municipality · NCT07761429

• F182112 versus standard care for relapsed or refractory multiple myeloma

  This study will test whether F182112 works better than standard treatments for adults whose multiple myeloma has come back or stopped responding after prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

  Recruiting Phase 3 Shandong New Time Pharmaceutical Co., LTD · Tianjing · NCT07579234

• F182112 given with other drugs for relapsed or refractory multiple myeloma

  This trial will test whether F182112, given with different drug regimens, helps people whose multiple myeloma has returned or stopped responding to prior treatments.

  Recruiting Phase 2 Shandong New Time Pharmaceutical Co., LTD · Tianjin · NCT07312188

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.